Willow Biosciences Inc. has advanced its work on its proprietary yeast strain for production of tetrahydrocannabinol (THC) and plans to commercially launch in the Canadian market.

The study compared the pharmacokinetic profiles of three of Caliper's proprietary soluble CBD formats against two control formats: oil-based CBD tincture and unemulsified CBD isolate.

Creo has produced cannabigerol (CBG) and cannabigerolic acid (CBGA) through fermentation at 12,500-liter scale, with performance matching or exceeding expectations.

As a zero-calorie, zero-sugar sparkling water formulated to suit three separate need occasions, Veryvell targets consumers with wellness in mind, says Truss CBD USA general manager Jane Armstrong Hockman.

Interest in the role of the cannabis derivative cannabidiol (CBD) in the wellness market has continued to rise, despite some concerns over safety and ongoing regulatory issues over its use. Its current growth spurt in new product activity started in 2018 and continued through 2019 and 2020 amid rising consumer awareness.

Open Book Extracts and Case Western Reserve University School of Medicine have entered into an agreement to explore the mechanistic effects of cannabinoids on brain cell functions.

Willow Biosciences Inc. has undertaken two initiatives to improve the understanding of cannabigerol (CBG), the company’s first commercial cannabinoid slated for production in the first quarter of 2021.

Founded by Chris Hetherington, Peels has secured a $4 million investment from KarpReilly, LLC, a Greenwich, Connecticut-based private investment firm.